[go: up one dir, main page]

WO2017014162A8 - アミロイドβ線維分解剤、アミロイドβの線維化に起因する疾患の治療薬・予防薬および治療用・予防用食品組成物 - Google Patents

アミロイドβ線維分解剤、アミロイドβの線維化に起因する疾患の治療薬・予防薬および治療用・予防用食品組成物 Download PDF

Info

Publication number
WO2017014162A8
WO2017014162A8 PCT/JP2016/070902 JP2016070902W WO2017014162A8 WO 2017014162 A8 WO2017014162 A8 WO 2017014162A8 JP 2016070902 W JP2016070902 W JP 2016070902W WO 2017014162 A8 WO2017014162 A8 WO 2017014162A8
Authority
WO
WIPO (PCT)
Prior art keywords
amyloid
therapeutic
fibril
preventive
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2016/070902
Other languages
English (en)
French (fr)
Other versions
WO2017014162A1 (ja
Inventor
陽一 石井
猛 岡本
さやか 石井
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Well Stone Co
Original Assignee
Well Stone Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP16827722.6A priority Critical patent/EP3326636A4/en
Priority to AU2016296962A priority patent/AU2016296962B2/en
Priority to CA2983905A priority patent/CA2983905A1/en
Priority to KR1020217014598A priority patent/KR102302013B1/ko
Priority to CN201680016841.9A priority patent/CN107405366B/zh
Priority to KR1020217028697A priority patent/KR20210114551A/ko
Priority to KR1020227031896A priority patent/KR20220131357A/ko
Priority to KR1020177030221A priority patent/KR102255146B1/ko
Priority to US15/577,464 priority patent/US20180147243A1/en
Application filed by Well Stone Co filed Critical Well Stone Co
Priority to RU2018105718A priority patent/RU2018105718A/ru
Priority to BR112017027209A priority patent/BR112017027209A2/pt
Publication of WO2017014162A1 publication Critical patent/WO2017014162A1/ja
Priority to PH12017501949A priority patent/PH12017501949A1/en
Publication of WO2017014162A8 publication Critical patent/WO2017014162A8/ja
Anticipated expiration legal-status Critical
Priority to AU2022200329A priority patent/AU2022200329B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23B—PRESERVATION OF FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES; CHEMICAL RIPENING OF FRUIT OR VEGETABLES
    • A23B2/00—Preservation of foods or foodstuffs, in general
    • A23B2/90—Preservation of foods or foodstuffs, in general by drying or kilning; Subsequent reconstitution
    • A23B2/92—Freeze drying
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L35/00—Foods or foodstuffs not provided for in groups A23L5/00 - A23L33/00; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/15—Inorganic Compounds
    • A23V2250/156—Mineral combination
    • A23V2250/16—Potassium
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/15—Inorganic Compounds
    • A23V2250/156—Mineral combination
    • A23V2250/161—Magnesium
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/15—Inorganic Compounds
    • A23V2250/156—Mineral combination
    • A23V2250/1614—Sodium
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2300/00—Processes
    • A23V2300/18—Fractionation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

天然物を有効成分として含有するアミロイドβ線維分解剤、アミロイドβの線維化に起因する疾患の治療薬または予防薬、アミロイドβの線維化に起因する疾患の治療用または予防用食品組成物を提供することにある。ミミズの乾燥粉末、摩砕物及び／又は抽出物を有効成分として含有する、アミロイドβ線維分解剤、アミロイドβの線維化に起因する疾患の治療薬または予防薬、アミロイドβの線維化に起因する疾患の治療用または予防用食品組成物である。アミロイドβの線維化に起因する疾患は、アルツハイマー病であることが好ましい。
PCT/JP2016/070902 2015-07-21 2016-07-14 アミロイドβ線維分解剤、アミロイドβの線維化に起因する疾患の治療薬・予防薬および治療用・予防用食品組成物 Ceased WO2017014162A1 (ja)

Priority Applications (13)

Application Number Priority Date Filing Date Title
US15/577,464 US20180147243A1 (en) 2015-07-21 2016-07-14 Amyloid beta fibril decomposing agent, and therapeutic or preventive agent and therapeutic or preventive food composition for diseases caused by amyloid beta fibril formation
CA2983905A CA2983905A1 (en) 2015-07-21 2016-07-14 Amyloid .beta. fibril decomposing agent, and therapeutic or preventive agent and therapeutic or preventive food composition for diseases caused by amyloid .beta. fibril formation
KR1020217014598A KR102302013B1 (ko) 2015-07-21 2016-07-14 아밀로이드β 섬유 분해제, 아밀로이드β의 섬유화에 기인하는 질환의 치료약·예방약 및 치료용·예방용 식품조성물
CN201680016841.9A CN107405366B (zh) 2015-07-21 2016-07-14 β淀粉样蛋白纤维分解剂、由β淀粉样蛋白的纤维化引起的疾病的治疗药/预防药
KR1020217028697A KR20210114551A (ko) 2015-07-21 2016-07-14 아밀로이드β 섬유 분해제, 아밀로이드β의 섬유화에 기인하는 질환의 치료약·예방약 및 치료용·예방용 식품조성물
KR1020227031896A KR20220131357A (ko) 2015-07-21 2016-07-14 아밀로이드β 섬유 분해제, 아밀로이드β의 섬유화에 기인하는 질환의 치료약·예방약 및 치료용·예방용 식품조성물
KR1020177030221A KR102255146B1 (ko) 2015-07-21 2016-07-14 아밀로이드β 섬유 분해제, 아밀로이드β의 섬유화에 기인하는 질환의 치료약·예방약 및 치료용·예방용 식품조성물
EP16827722.6A EP3326636A4 (en) 2015-07-21 2016-07-14 MEDIUM FOR THE REMOVAL OF AMYLOID BETA FIBRILLES AND A THERAPEUTIC OR PREVENTIVE AGENT AND THERAPEUTIC OR PREVENTIVE FOOD COMPOSITION FOR DISEASES CAUSED BY AMYLOID BETA FIBRILLATION
RU2018105718A RU2018105718A (ru) 2015-07-21 2016-07-14 СРЕДСТВО, РАЗРУШАЮЩЕЕ ФИБРИЛЛЫ АМИЛОИДА β, И ТЕРАПЕВТИЧЕСКИЙ ИЛИ ПРОФИЛАКТИЧЕСКИЙ АГЕНТ, И ТЕРАПЕВТИЧЕСКАЯ ИЛИ ПРОФИЛАКТИЧЕСКАЯ ПИЩЕВАЯ КОМПОЗИЦИЯ ДЛЯ ЗАБОЛЕВАНИЙ, ВЫЗВАННЫХ ОБРАЗОВАНИЕМ ФИБРИЛЛ АМИЛОИДА β
AU2016296962A AU2016296962B2 (en) 2015-07-21 2016-07-14 Amyloid beta fibril decomposing agent, and therapeutic or preventive agent and therapeutic or preventive food composition for diseases caused by amyloid beta fibril formation
BR112017027209A BR112017027209A2 (pt) 2015-07-21 2016-07-14 agente de decomposição de fibrila beta amiloide e agente terapêutico ou de prevenção e composição alimentícia terapêutica ou de prevenção de doenças causadas pela formação de fibrila beta amiloide
PH12017501949A PH12017501949A1 (en) 2015-07-21 2017-10-25 Amyloid � fibril decomposing agent, and therapeutic or preventive agent and therapeutic or preventive food composition for diseases caused by amyloid � fibril formation
AU2022200329A AU2022200329B2 (en) 2015-07-21 2022-01-19 Amyloid beta fibril decomposing agent, and therapeutic or preventive agent and therapeutic or preventive food composition for diseases caused by amyloid beta fibril formation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015144319A JP2017025019A (ja) 2015-07-21 2015-07-21 アミロイドβ線維分解剤、アミロイドβの線維化に起因する疾患の治療薬・予防薬および治療用・予防用食品組成物
JP2015-144319 2015-07-21

Publications (2)

Publication Number Publication Date
WO2017014162A1 WO2017014162A1 (ja) 2017-01-26
WO2017014162A8 true WO2017014162A8 (ja) 2017-11-16

Family

ID=57834025

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2016/070902 Ceased WO2017014162A1 (ja) 2015-07-21 2016-07-14 アミロイドβ線維分解剤、アミロイドβの線維化に起因する疾患の治療薬・予防薬および治療用・予防用食品組成物

Country Status (12)

Country Link
US (1) US20180147243A1 (ja)
EP (1) EP3326636A4 (ja)
JP (1) JP2017025019A (ja)
KR (4) KR102302013B1 (ja)
CN (1) CN107405366B (ja)
AU (2) AU2016296962B2 (ja)
BR (1) BR112017027209A2 (ja)
CA (1) CA2983905A1 (ja)
PH (1) PH12017501949A1 (ja)
RU (1) RU2018105718A (ja)
TW (1) TWI781082B (ja)
WO (1) WO2017014162A1 (ja)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6253837B1 (ja) * 2017-07-18 2017-12-27 エンチーム株式会社 組成物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08283157A (ja) 1995-02-15 1996-10-29 Takeda Chem Ind Ltd アミロイドβ蛋白産生・分泌阻害剤
JP4227245B2 (ja) 1999-04-30 2009-02-18 パナソニック株式会社 磁気ディスク用基板の製造方法
CN1753662A (zh) * 2002-12-24 2006-03-29 神经化学（国际）有限公司 用于治疗β－淀粉状蛋白相关疾病的治疗制剂
ITRM20050045A1 (it) * 2005-02-02 2006-08-03 Consiglio Nazionale Ricerche Proteina isolata da eisenia foetida simile all'ngf umano e usi relativi.
US8101578B2 (en) 2006-04-28 2012-01-24 Kagoshima University Amyloid [β] Beta fibrillogenesis-inhibiting peptide
JP4699974B2 (ja) * 2006-09-29 2011-06-15 Ｗｅｌｌ Ｓｔｏｎｅ 有限会社 ミミズ乾燥粉末の製造方法
US8137701B2 (en) * 2008-03-21 2012-03-20 Well Stone Co. Method of producing a dry earthworm powder
JP2009249362A (ja) * 2008-04-09 2009-10-29 Ｗｅｌｌ Ｓｔｏｎｅ 有限会社 無害化されたミミズ乾燥粉末の製造方法
US8137666B2 (en) * 2008-11-22 2012-03-20 Academia Sinica Nattokinase for degrading and reducing amyloid fibrils—associated with alzheimer's disease, prion diseases and other amyloidoses
JP4886017B2 (ja) * 2009-10-13 2012-02-29 Ｗｅｌｌ Ｓｔｏｎｅ 有限会社 ミミズ乾燥粉末の製造方法
JP4808822B1 (ja) * 2011-04-11 2011-11-02 Ｗｅｌｌ Ｓｔｏｎｅ 有限会社 ミミズ乾燥粉末の製造方法
CN103702661B (zh) * 2011-07-29 2015-10-07 井石有限会社 使用了蚯蚓干燥粉末的酪氨酸酶抑制剂及其制造方法
CN103550537B (zh) * 2013-11-10 2014-08-06 孟晓彬 一种治疗阿尔茨海默病的中药制剂及制备方法
US10155012B2 (en) * 2014-01-20 2018-12-18 Well Stone Co. Catecholamine production accelerator, and therapeutic and preventive agent and therapeutic and preventive food composition for diseases caused by catecholamine deficiency
CN104288396A (zh) * 2014-09-27 2015-01-21 隋荣玲 一种治疗老年痴呆症的中药汤剂
JP6321521B2 (ja) * 2014-11-04 2018-05-09 Ｗｅｌｌ Ｓｔｏｎｅ 有限会社 タウ蛋白産生促進剤、タウ蛋白の欠乏に起因する疾患の治療薬・予防薬および治療用・予防用食品組成物
CN104547388A (zh) * 2014-12-18 2015-04-29 黑龙江儒泰生物制药有限责任公司 治疗阿尔茨海默病的中药组合物、其制备方法和用途

Also Published As

Publication number Publication date
KR20180029950A (ko) 2018-03-21
AU2022200329A1 (en) 2022-02-17
AU2016296962B2 (en) 2021-10-28
RU2018105718A (ru) 2019-08-22
BR112017027209A2 (pt) 2018-10-30
WO2017014162A1 (ja) 2017-01-26
CN107405366A (zh) 2017-11-28
AU2016296962A1 (en) 2018-01-04
US20180147243A1 (en) 2018-05-31
CA2983905A1 (en) 2017-01-26
KR102302013B1 (ko) 2021-09-13
KR20210114551A (ko) 2021-09-23
KR20220131357A (ko) 2022-09-27
EP3326636A1 (en) 2018-05-30
JP2017025019A (ja) 2017-02-02
KR102255146B1 (ko) 2021-05-21
TWI781082B (zh) 2022-10-21
KR20210059023A (ko) 2021-05-24
EP3326636A4 (en) 2019-03-27
PH12017501949A1 (en) 2018-03-19
AU2022200329B2 (en) 2023-10-05
CN107405366B (zh) 2022-07-22
TW201716073A (zh) 2017-05-16

Similar Documents

Publication Publication Date Title
PH12020550341A1 (en) Niraparib formulations
PH12018502268A1 (en) Amide-substituted pyridinyltriazole derivatives and uses thereof
TN2017000467A1 (en) Amido-substituted cyclohexane derivatives
SG10201808104RA (en) Cenicriviroc for the treatment of fibrosis
EA201290836A1 (ru) Связанные бис-арильные арилтриазолоны и их применение
WO2016190683A8 (ko) 길경 추출물을 함유하는 근육 질환 예방 및 치료용 또는 근 기능 개선용 조성물
EA201992607A1 (ru) Твердые формы берберина урсодезоксихолата, их композиции и способы
WO2017022962A8 (ko) Ripk 억제제를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물
JOP20180071B1 (ar) استخدام مشتقات أمينو ألكيل بنزوثيازبين
WO2016190682A3 (ko) 모루신, 구와논 지 또는 상백피를 함유하는 근육 질환 예방 및 치료용 또는 근 기능 개선용 조성물
EA201890449A1 (ru) Фумагиллиновые гетероциклические соединения и способы их получения и применения
WO2016004404A3 (en) Gls1 inhibitors for treating disease
EP3231436A4 (en) Pharmaceutical composition for prevention or treatment of metabolic disease, comprising bacteroides acidifaciens as effective ingredient
EP4272832A3 (en) Antimicrobial compounds, compositions, and uses thereof
MX394161B (es) Nuevo extracto de aquenio silybum marianum y usos del mismo en la dermatología y dermocosméticos.
WO2016006974A3 (en) Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof
WO2016006975A3 (en) Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof
WO2016072392A8 (ja) タウ蛋白産生促進剤、タウ蛋白の欠乏に起因する疾患の治療薬・予防薬および治療用・予防用食品組成物
PH12016501205B1 (en) Catecholamine production accelerator, and therapeutic and preventive agent and therapeutic and preventive food composition for diseases caused by catecholamine deficiency
WO2015044961A3 (en) Pharmaceutical composition comprising capecitabine and cyclophosphamide
WO2017014162A8 (ja) アミロイドβ線維分解剤、アミロイドβの線維化に起因する疾患の治療薬・予防薬および治療用・予防用食品組成物
MX381932B (es) Composicion intranasal que comprende betahistina.
PH12019500024A1 (en) Pharmaceutical compositions
WO2016027225A8 (en) A composition having a muscle-relaxant and anti-inflammatory activity
PH12020500120A1 (en) Pharmaceutical compositions

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16827722

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 20177030221

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2983905

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 12017501949

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 15577464

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2016296962

Country of ref document: AU

Date of ref document: 20160714

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2018105718

Country of ref document: RU

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112017027209

Country of ref document: BR

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: 112017027209

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112017027209

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20171215

WWW Wipo information: withdrawn in national office

Ref document number: 2016827722

Country of ref document: EP